Skip to main content
  1. Home
  2. Emerging Tech
  3. News

NASA will hand over the ISS to a private company in about a decade

Add as a preferred source on Google

A very lucky company may be able to get its hands on one of the most coveted pieces of real estate in the universe — a property that’s quite literally out of this world.

During a Thursday press conference, NASA Deputy Associate Administrator for Exploration Systems Development Bill Hill suggested that the space agency hopes to hand over the keys of the International Space Station to a commercial owner, Digital Trends can confirm. The move is expected to take place within the next decade, with the “mid-2020s” serving as a goal.

Recommended Videos

“NASA’s trying to develop economic development in low-earth orbit,” said Hill, speaking as part of a NASA panel discussing the upcoming “Journey to Mars” mission. “Ultimately, our desire is to hand the space station over to either a commercial entity or some other commercial capability so that research can continue in low-Earth orbit.”

Another NASA employee told Digital Trends that the transfer of the ISS to commercial companies is already well underway, and the influx in commercial launches to the ISS ought to reduce NASA’s overall involvement in this particular project.

The decision isn’t particularly surprising as the American government has only set aside funds for the ISS to remain in orbit through 2024 — at least, on the federal government’s dime. President Barack Obama has already extended ISS operations: The deorbiting date was initially set for 2016. The extra time was deemed necessary for NASA to better prepare for its next big goal, a trip to the Red Planet.

At the press conference, NASA didn’t mention any possible buyers, though both Boeing and SpaceX seem like likely contenders. After all, both companies are slated to make trips of their own to the ISS, serving as shuttles for astronauts looking to go between Earth and their outer space home. SpaceX also has grand plans of its own to make its way to Mars.

Lulu Chang
Fascinated by the effects of technology on human interaction, Lulu believes that if her parents can use your new app…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more